Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.
Saved in:
| Title: | Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks. |
|---|---|
| Authors: | Petersen KK; Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA., Milà-Alomà M; Northern California Institute for Research and Education, San Francisco, CA, USA.; Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA., Li Y; Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA., Du L; Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.; Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.; Rush Alzheimer's Disease Center, Chicago, IL, USA.; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA., Xiong C; Knight Alzheimer Disease Research Center, St. Louis, MO, USA.; Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA., Tosun D; Northern California Institute for Research and Education, San Francisco, CA, USA.; Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA., Saef B; Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA., Saad ZS; Precision Measures, Johnson & Johnson, San Diego, CA, USA., Du-Cuny L; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany., Coomaraswamy J; Takeda Pharmaceutical Company Ltd., Cambridge, MA, USA., Mordashova Y; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany., Rubel CE; Biogen, Cambridge, MA, USA., Meyers EA; Alzheimer's Association, Chicago, IL, USA., Shaw LM; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Dage JL; Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.; Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA., Ashton NJ; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.; Banner Alzheimer's Institute, Phoenix, AZ, USA.; Banner Sun Health Research Institute, Sun City, AZ, USA., Zetterberg H; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; UK Dementia Research Institute Fluid Biomarkers Laboratory, UK DRI at UCL, London, UK.; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.; Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA., Ferber K; Biogen, Cambridge, MA, USA., Triana-Baltzer G; Precision Measures, Johnson & Johnson, San Diego, CA, USA., Baratta M; Takeda Pharmaceutical Company Ltd., Cambridge, MA, USA., Rosenbaugh EG; Foundation for the National Institutes of Health, North Bethesda, MD, USA., Cruchaga C; Knight Alzheimer Disease Research Center, St. Louis, MO, USA.; Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.; NeuroGenomics and Informatics Center, Washington University, St. Louis, MO, USA.; Hope Center for Neurologic Diseases, St. Louis, MO, USA., McDade E; Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.; Knight Alzheimer Disease Research Center, St. Louis, MO, USA., Holtzman DM; Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.; Knight Alzheimer Disease Research Center, St. Louis, MO, USA.; Hope Center for Neurologic Diseases, St. Louis, MO, USA., Morris JC; Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.; Knight Alzheimer Disease Research Center, St. Louis, MO, USA., Sabandal JM; Foundation for the National Institutes of Health, North Bethesda, MD, USA., Bateman RJ; Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.; Knight Alzheimer Disease Research Center, St. Louis, MO, USA.; Hope Center for Neurologic Diseases, St. Louis, MO, USA.; Tracy Family SILQ Center for Neurodegenerative Biology, St. Louis, MO, USA., Bannon AW; AbbVie, North Chicago, IL, USA., Potter WZ, Schindler SE; Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA. schindlers@neuro.wustl.edu.; Knight Alzheimer Disease Research Center, St. Louis, MO, USA. schindlers@neuro.wustl.edu.; Hope Center for Neurologic Diseases, St. Louis, MO, USA. schindlers@neuro.wustl.edu. |
| Corporate Authors: | Alzheimer’s Disease Neuroimaging Initiative (ADNI), Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer’s Disease Project Team |
| Source: | Nature medicine [Nat Med] 2026 Mar; Vol. 32 (3), pp. 1085-1094. Date of Electronic Publication: 2026 Feb 19. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
